Comparative Pharmacology
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus NOVOCAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus NOVOCAIN.
HEAVY SOLUTION NUPERCAINE vs NOVOCAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heavy solution nupercaine (dibucaine) is a potent, long-acting amide local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the propagation of action potentials and preventing nerve impulse conduction.
Procaine, an ester-type local anesthetic, reversibly binds to the intracellular portion of voltage-gated sodium channels, inhibiting sodium influx and blocking nerve impulse conduction.
Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.
Local infiltration: 0.5% solution, up to 20 mL (100 mg) per dose; nerve block: 1-2% solution, 5-10 mL (50-200 mg); maximum single dose: 7 mg/kg or 350 mg (without epinephrine).
None Documented
None Documented
Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Plasma half-life: approximately 30–60 seconds due to rapid hydrolysis by pseudocholinesterases; clinical effects short-lived.
Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Renal excretion of para-aminobenzoic acid (PABA) and diethylaminoethanol as major metabolites; <2% excreted unchanged in urine. Biliary/fecal: minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic